Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Corvus Pharma Com (CRVS)

Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors GlobeNewswire - Thu Apr 23, 6:30AM CDT

SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D., Ph.D.,...

CRVS : 15.46 (+1.78%)
Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting GlobeNewswire - Tue Apr 21, 6:30AM CDT

Two oral presentations including late-breaker at SID  Data will cover Phase 1 clinical trial of soquelitinib for atopic dermatitis, including new immunologic and biomarker data supporting drug-free...

CRVS : 15.46 (+1.78%)
New York Stock Exchange during sunrise by Deberarr via iStock
Stock Index Futures Gain on Hopes for U.S.-Iran Deal, Netflix Sinks on Disappointing Guidance Barchart - Fri Apr 17, 5:33AM CDT

June S&P 500 E-Mini futures (ESM26) are up +0.23%, and June Nasdaq 100 E-Mini futures (NQM26) are up +0.20% this morning as investors take on more risk amid mounting speculation that a deal to end the...

NFLX : 92.06 (-1.66%)
AA : 62.63 (-1.82%)
JBHT : 248.73 (-1.11%)
ALLY : 43.41 (-1.54%)
ORCL : 171.83 (+6.47%)
ESM26 : 7,258.00s (+0.20%)
TFC : 50.93 (-1.11%)
FITB : 50.43 (-0.65%)
STT : 152.00 (-0.55%)
CRVS : 15.46 (+1.78%)
RF : 28.19 (-1.26%)
ALB : 193.88 (-1.43%)
Corvus: Q4 Earnings Snapshot AP - Thu Mar 12, 3:16PM CDT

Corvus: Q4 Earnings Snapshot

CRVS : 15.46 (+1.78%)
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results GlobeNewswire - Thu Mar 12, 3:01PM CDT

Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiated...

CRVS : 15.46 (+1.78%)
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 GlobeNewswire - Thu Mar 5, 3:01PM CST

SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference...

CRVS : 15.46 (+1.78%)
Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference GlobeNewswire - Mon Feb 23, 3:01PM CST

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership...

CRVS : 15.46 (+1.78%)
MarketBeat.com
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026 MarketBeat - Mon Feb 2, 9:39AM CST

Three standout stocks for 2026 have already generated massive returns of 56% or more this year, although they may cater to investors with a tolerance for risk.

CRVS : 15.46 (+1.78%)
USAR : 26.33 (+1.39%)
NUAI : 4.04 (+2.54%)
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M GlobeNewswire - Fri Jan 23, 4:00PM CST

SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underwritten...

CRVS : 15.46 (+1.78%)
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock GlobeNewswire - Wed Jan 21, 9:53PM CST

SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an upsized underwritten...

CRVS : 15.46 (+1.78%)

Barchart Exclusives

These Are April's 2 Hottest AI Stocks. Should You Buy Them in May? Barchart - Sat May 2, 10:30AM CDT
These AI winners surged in April, but upcoming earnings will decide if their rally has more room to run. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.